Canaccord lowered the firm’s price target on Clover Health (CLOV) to $3.70 from $4.10 and keeps a Buy rating on the shares. The firm said Clover’s return to significant growth during last year’s AEP and throughout 2025 when membership in its MA plans expanded rapidly finally caught up to the company in 3Q with a sizable adj-EBITDA miss and downward profitability guidance revision as elevated medical cost trend materialized in the quarter along with prior period development from 1H’25.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLOV: